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Abstract 25 
 26 
Infusion medical devices (MDs) used in hospitals are often made of plasticized polyvinylchloride 27 
(PVC). These plasticizers may leach out into infused solutions during clinical practice, especially 28 
during risk-situations, e.g multiple infusions in Intensive Care Units and thus may enter into contact 29 
with the patients. The migrability of the plasticizers is dependent of several clinical parameters such 30 
as temperature, contact time, nature of the simulant, etc… However, no data is available about the 31 
influence of the flow rate at which drug solutions are administrated. In this study, we evaluated the 32 
impact of different flow rates on the release of the different plasticizers during an infusion 33 
procedure in order to assess if they could expose the patients to more toxic amounts of plasticizers. 34 
Migration assays with different PVC infusion sets and extension lines were performed with different 35 
flow rates that are used in clinical practice during 1h, 2h, 4h, 8h and 24h, using a lipophilic drug 36 
simulant. 37 
From a clinical point of view, the results showed that, regardless of the plasticizer, the faster the 38 
flow rate, the higher the infused volume and the higher the quantities of plasticizers released, both 39 
from infusion sets and extension lines, leading to higher patient exposure. However, physically, 40 
there was no significant difference of the migration kinetics linked to the flow rate for a same 41 
medical device, reflecting complex interactions between the PVC matrix and the simulant. The 42 
migration was especially dependent on the nature and the composition of the medical device.  43 
 44 
 45 
 46 
 47 
 48 
 49 
Introduction 50 
 51 
In the field of infusion, numerous medical devices, such as infusion sets and extension lines are used 52 
in various simple or complex assemblies. Most of them are manufactured in PVC plasticized with 53 
alternatives to di-(ethylhexyl)-phthalate (DEHP) plasticizers, e.g. di-(ethylhexyl)-terephthalate 54 
(DEHT), di-isononyl-1,2-cyclohexane-dicarboxylate (DINCH) or trioctyl trimellitate (TOTM) and 55 
diisononyl phthalate (DINP). They have greatly replaced DEHP since it is likely to present a danger to 56 
the patient, and  has now been classed as a CMR1b risk substance due to its effects on reproduction 57 
and fertility (1). Thus, it now must not exceed 0.1% by mass of the plasticized material, as defined 58 
 3 
by the European regulation concerning the Registration, Evaluation, Authorization and Restriction 59 
of Chemical substances (REACH). Furthermore, according to decree of 13th April 2017, its use in 60 
tubings used in pediatric, neonatal, and maternity units has been restricted in France above a 61 
threshold level of 0.1% (2) 62 
 63 
However, only very limited data is available regarding the risk associated to the migration of the 64 
alternative plasticizers from the medical devices, especially in at risk-situations like multiple 65 
infusions in Intensive Care Units (ICU). To assess the exposure risk of inpatients, the evaluation of 66 
their migration in such conditions is required. An infusion model was developed to estimate if a 67 
medical device could be considered safe for infusion use according to the leaching of plasticizers (3). 68 
Nevertheless, this model doesn’t take into account of the flow rate at which drug solutions are 69 
administrated to the patients, thus considering the exposure risk to be the same whatever the flow 70 
rate of the infusion. Bagel et al demonstrated that the extraction of DEHP was encouraged in static 71 
conditions (4) but no study has evaluated the influence of this parameter with alternative 72 
plasticizers. 73 
The aim of this work was to evaluate the impact of different flow rates on the release of four 74 
plasticizers (TOTM, DINP, DEHT and DINP) during an infusion and to assess different infusion rates 75 
that could expose the patient to more toxic amounts of plasticizers. From this basis, it could be 76 
discussed whether the infusion model should be adapted and eventually if reduction factors linked 77 
to the flow rate should be applied, correcting the specific migration with low or high flow rates (as it 78 
has been done in the regulation 10/2011 (5) with food containing more than 20% fat). 79 
To this end, we tested different flow rates usually applied in clinical practice through 80 
infusion sets and extension lines. This study should finally help us to understand which mechanisms 81 
govern migration phenomena of alternative plasticizers. 82 
 83 
Materials and methods 84 
 85 
 Samples 86 
MDs used for the migration assays were extension lines and infusion sets, which are commonly 87 
used in the field of infusion. They were selected specifically because they contain one specific 88 
different plasticizer each (TOTM, DEHT, DINCH or DINP) without any trace of carcinogenic, 89 
mutagenic, reprotoxic 1b (CMR1b) phthalates, as announced by their manufacturer. To allow 90 
 4 
correct comparability, each device was also chosen so as to have the same technical features in 91 
terms of the tube thickness (which is approximately 0.75mm for the extension lines and 0.6mm for 92 
the infusion sets). 93 
The characteristics of the chosen medical devices are presented in tables 1 and 2. 94 
 95 
Table 1: characteristics of PVC tubings from extension lines used in the migration study 96 
Supplier Cair LGL Codan B Braun Sendal Cair LGL Cair LGL 
Reference PES 3301 M E-87 P 0086670 D Prolonsend PN 3301 M PN 3101 M 
Batch 15D13T H71654-1 14N02F8SPA 03446 13E21-TN 12H07-TN 
Designation EL 1 EL 2 EL 3 EL 4 EL 5 EL 6 
Length (cm) 13.9 96.5 11.2 11.0 10.2 10.5 
Weight of PVC tubing 
(mg) 
1286.8 2837.8 1050.4 893.1 992.0 506.8 
Inner diameter (cm) 0.25 0.10 0.25 0.30 0.25 0.10 
Internal surface (cm2) 10.91 30.30 8.79 10.36 8.01 3.30 
Volume (mL) 0.682 0.757 0.550 0.777 0.500 0.082 
Co-extruded (PVC/PE) Yes No No No No No 
Announced plasticizer TOTM TOTM DEHT DINP DINCH DINCH 
 97 
Table 2: characteristics of PVC tubings from infusion sets used in the migration study 98 
Supplier B Braun CareFusion Doran 
International 
Codan 
Reference 4063007 A64 INFU-R3 43.4535 
Batch 039615B13A8421 0396 1411247 L85603-1 
Designation IS 1 IS 2 IS 3 IS 4 
Length (cm) 179.0 145.7 181.7 173.8 
Weight of PVC tubing (mg) 12975.5 11470.7 15052.2 12258.5 
Inner diameter (cm) 0.27 0.27 0.25 0.30 
Internal surface (cm2) 154.6 124.4 141.5 170.3 
Volume (mL) 10.4 8.5 8.8 13.3 
Co-extruded (PVC/PE) No No No No 
Announced plasticizer DEHT DINP DINCH TOTM 
 99 
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 100 
Migration assays 101 
 102 
Analysis of plasticizers in PVC tubings 103 
Before performing migration tests, the exact composition of plasticizers  present in each PVC tubing 104 
was determined by GC-MS after a solvent extraction using the published method described by 105 
Bourdeaux et al (6). 106 
This analysis allowed us to identify and quantify the main plasticizer present in the PVC matrix as 107 
well as the minority ones, which could be found as impurities and could also be released from the 108 
devices. 109 
 110 
Study design 111 
 112 
Conditions of the migration assays 113 
Migration assays were performed in the same conditions described by Bernard et al as regard to the 114 
choice of the simulant, and of the contact temperature and time (3). Only the flow rate was 115 
modified. 116 
The used parameters were as follows: 117 
- simulant: we chose a 50/50 ethanol/water (v/v) solution which reflects lipid emulsions able to 118 
extract plasticizers from PVC medical devices. 3% acetic acid (also proposed in the infusion model) 119 
was not selected because the migration appears to be insignificant in it (3). 120 
- contact temperature: 25°C was chosen to perform the tests as it corresponds to the ambient 121 
temperature most commonly found in adult health care units. 122 
- contact time: the infusion tests were performed during 24h in order to mimic the maximal time 123 
period  of an injectable drug infusion containing lipids. 124 
 125 
Administration methodology 126 
Based on clinical practices, assays were performed under different flow rates that are usually 127 
applied from a syringe pump for the administration of drugs and on infusion sets for gravity 128 
administrations. The conditions were the following: 129 
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- for the tests with extension lines, the syringes were filled with the ethanolic simulant and the 130 
extension line was set on the syringe. Then one of the following flow rates was applied during 24 131 
hours: 1mL/h, 5mL/h and 10mL/h 132 
- for the tests with infusion sets, non-PVC bags were filled with the ethanolic solution and set on the 133 
infusion set. Then one of the following flow rates was applied during 24 hours: 8mL/h, 20mL/h, 134 
50mL/h and 100mL/h 135 
The 8mL/h flow rate was specifically chosen since it is in accordance with the clinical ratio 136 
volume/surface of 2L/13dm2 recommended in the infusion model of Bernard et al. (all the infusion 137 
sets tested in this work have similar inner surface in contact with simulant). The other flow rates 138 
correspond to those usually set up in clinical practice: the lower ones with extension lines allow the 139 
continuous administration of narrow therapeutic range drugs (e.g amines, anaesthetics, insulin, 140 
etc…) whereas the higher ones are used for injectable chemotherapy or antibiotherapy drugs. 141 
 142 
Kinetic study 143 
In order to study the migration mechanisms, we performed a kinetic study by analysing the 144 
cumulated amount of plasticizers released into the simulant at different contact times: 1h, 2h, 4h, 145 
8h and 24h. For each contact time, assays were performed in triplicate. 146 
 147 
Analysis of plasticizer into the simulant 148 
The amount of plasticizers released into the simulant was assessed by gas chromatography coupled 149 
with mass spectrometry (GC-MS) (6) after extraction from the simulant. To perform this extraction, 150 
600 μl of the ethanolic solution was taken and added to 600 μl of a 2 μg/mL of 151 
(benzylbutylphtalate) BBP solution in chloroform. After homogenization (with vortex 20 Hz, 30 152 
seconds), the samples were centrifuged (3500 rpm, 5min). Finally, the chloroform phase (below the 153 
aqueous phase) was taken for GC-MS analysis. 154 
 155 
As plasticizers are widely present in the environment, to prevent the risk of contamination, the used 156 
glass flasks were washed 3 times with chloroform before performing the assays; hemolysis tubes 157 
and GC-MS vials were single use. 158 
 159 
Expression of the results 160 
 161 
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- The initial amount of each plasticizer in the tubing samples was expressed in mass percent (%) 162 
(mean ± standard deviation) 163 
- Two different approaches were undertaken to verify the impact of the flow rate on the release of 164 
the plasticizers:  165 
1- a “clinical approach“ which gives the amounts of plasticizers able to migrated to patients. 166 
The amounts of each plasticizer released into the simulant were expressed in two manners: 167 
- the mass (μg) of the plasticizer released into the simulant 168 
- this amount was then compared with the initial weight of the PVC sample (mg). It is 169 
expressed in mg of migrated plasticizer per 100g of PVC 170 
2- a “physicochemical approach” which provides the results of release by standardizing the 171 
features of the MD and the volume infused. The migration kinetic was expressed as follow: 172 
 173 
 174 
A = migration kinetic (µg/dm²/mL) 175 
q = quantity of plasticizer released into the simulant (µg) during the migration assay 176 
s = area of MD in contact with the simulant (dm²) during the migration assay 177 
v = infused volume during the migration assay (mL) 178 
 179 
 180 
Statistical analysis 181 
All statistical analyses were performed using Stata statistical software (version 13, StataCorp, 182 
College Station, US). The tests were two-sided, with a type I error set at α=0.05. Continuous 183 
parameters were expressed as mean ± standard-deviation according to statistical distribution 184 
(assumption of normality studied using Shapiro-Wilk’s test). To study longitudinal evolution, 185 
correlated repeated data was analyzed using linear mixed models: (1) quantity of plasticizers 186 
released during migration assays from the extension lines and from the infusion tests and (2) kinetic 187 
of migration of plasticizers. This approach seems more relevant rather than usual statistical tests 188 
because assumption concerning independence of data is not met. The (fixed) effects group, time-189 
point evaluation and their interactions time/flow rate were studied. The normality of residuals 190 
obtained from these models was analyzed as described previously. Bayesian Information Criterion 191 
(BIC) was estimated to determine the most appropriate model, notably concerning the covariance 192 
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structure for the random-effects due to repeated measures across the time and consequently to 193 
the autocorrelation. 194 
This approach seems more relevant rather than usual statistical tests because assumption 195 
concerning independence of data has not been reach met 196 
 197 
Results  198 
 199 
 200 
Plasticizers in PVC tubings 201 
 202 
Table 3 shows the nature and the amount of plasticizers in each PVC medical device as analyzed by 203 
GC-MS. 204 
 205 
 206 
Table 3 : Qualitative and quantitative composition in plasticizers of the studied medical devices 207 
Type of PVC 
medical device 
Medical device 
(MD) 
Nature of 
plasticizer in MD 
Quantity of plasticizer 
in MD (expressed in 
mass percent) 
Extension line EL n°1 (Cair) TOTM 
DEHT 
DEHP 
31.81 
0.06 
<LOQ* 
EL n°2 (Codan) TOTM 
DEHT 
DEHP 
30.29 
0.05 
<LOQ* 
EL n°3 (BBraun) DEHT 26.74 
EL n°4 (Sendal) DINP 
DEHP 
48.72 
0.25 
EL n°5 (Cair GM) DINCH 30.16 
EL n°6 (Cair PM) DINCH 35.73 
Infusion set IS n°1 DEHT 37.50 
IS n°2 DINP 34.89 
IS n°3 DINCH 
DEHP 
44.27 
0.05 
IS n°4 TOTM 
DEHT 
DEHP 
40.97 
0.15 
0.002 
* LOQ = limit of quantification 208 
EL = extension line 209 
IS = infusion set 210 
 211 
 212 
Plasticizers migration during infusion: the clinical approach 213 
 214 
 215 
Figures 1 and 2 show the results of the migration assays of the main plasticizers from the 6 tested 216 
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extension lines and the 4 infusion sets. 217 
Figure 1 : Quantity of plasticizers released during migration assays (3 flow rates tested: 1mL/h; 218 
5mL/h and 10mL/h – 5 contact times: 1h, 2h, 4h, 8h and 24h) from the 6 extension lines (EL) 219 
tested. (n= 3; mean +/- standard deviation) 220 
 221 
Figure 2 : Quantity of plasticizers released during migration assays (4 flow rates tested: 8mL/h; 222 
20mL/h; 50mL/h and 100mL/h – 5 contact times: 1h, 2h, 4h, 8h and 24h) from the 4 infusion sets 223 
tested. (n= 3, mean +/- standard deviation) 224 
 225 
The quantity of plasticizers released into the simulant raises gradually during the infusion period, 226 
regardless the type of device and the plasticizer integrated into the PVC. 227 
The amounts of plasticizers released at the end of the procedure (24h) are different according the 228 
flow rate: the higher the flow rate, the higher the infused volume and the higher the quantities of 229 
plasticizers released, both from infusion sets and extension lines.  230 
For examples, by comparing the highest and the lowest flow rates in both migration studies 231 
(100mL/h vs 8mL/h with infusion sets and 10mL/h vs 1mL/h with extension lines), the ratios of the 232 
amounts of plasticizers released at each flow rate are 6.9 and 8; 3.6 and 2.7; 3.35 and 2.6 and 2.3 233 
and 1.7 for TOTM, DEHT, DINCH and DINP respectively. 234 
 235 
Regarding both extension lines of PVC/TOTM, TOTM migration is more important when the device 236 
doesn’t possess an internal layer of polyethylene. The quantities of TOTM released are about ten 237 
times higher than those released from the coextruded extension line, regardless of the flow rate. 238 
 239 
The inner diameter of the tubing does not have any impact on the migration of DINCH. Indeed, the 240 
total amounts of DINCH released from the EL5 and the EL6 are quite similar (for an inner diameter 241 
of 0.25 and 0.1 cm, respectively) whatever the kinetic time. 242 
 243 
Figures 3 and 4 show the percentages of the initial amounts of DEHT, TOTM, DINCH and DINP 244 
having migrated from the extension lines and the infusion sets at 24h as a function of the flow rate 245 
set. 246 
Figure 3 : Comparison of the migration of plasticizers from the extension lines at 24h according 247 
the flow rate (n = 3, mean +/- standard deviation) 248 
Figure 4 : Comparison of the migration of plasticizers from the infusion sets at 24h according the 249 
flow rate (n = 3, mean +/- standard deviation) 250 
 251 
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Under identical dynamic experimental conditions, the plasticizers demonstrated different migration 252 
abilities within the first 24 h of contact. Regardless the flow rate, DINP and DINCH had the highest 253 
degrees of migration in dynamic conditions compared to TOTM and DEHT.  254 
 255 
 256 
Plasticizers migration during infusion: the physicochemical approach 257 
 258 
The figures 5 and 6 show the quantities of the different plasticizers released from the MD expressed 259 
by unit area of MD in contact with the simulant (dm2), by unit volume infused (mL) during the 260 
infusion procedure. The application of a lower flow rate may extract more plasticizer at each time of 261 
the kinetic, regardless of the plasticizer and the type of device. The findings of statistical analyses 262 
reported in tables 4 and 5 are thus consistent except for DEHT from the infusion sets for which 263 
results show an important variability. 264 
 265 
Figure 5 : Kinetics of the plasticizer’s migration expressed in μg/dm2/mL from the 6 extension 266 
lines (3 flow rates tested: 1mL/h; 5mL/h and 10mL/h – 5 contact times: 1h, 2h, 4h, 8h and 24h).  267 
(n = 3, mean +/- standard deviation) 268 
 269 
Figure 6: Kinetics of the plasticizer’s migration expressed in μg/dm2/mL from the 4 infusion sets (4 270 
flow rates tested: 8mL/h; 20mL/h; 50mL/h and 100mL/h – 5 contact times: 1h, 2h, 4h, 8h and 271 
24h). (n = 3, mean +/- standard deviation) 272 
 273 
However, except for the non-coextruded extension line (EL2), tables 4 and 5 show that the 274 
migration kinetic profiles of each plasticizer are similar at any time, without any significant 275 
difference in the interactions between time and flow rate; in other words the variation over time 276 
was not significantly different between plasticizers.  277 
 278 
As with the « clinical approach », TOTM migration, expressed in mg/dm2/mL, is different between 279 
PVC tubings and PVC/PE tubings. TOTM release is 5 times, 3 times and 2.5 times lower from the 280 
coextruded extension line (EL 1) than that from the non-coextruded one (EL 2) at respectively 281 
10mL/h, 5mL/h and 1mL/h. 282 
 283 
 284 
  285 
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 286 
Table 4 : Statistical analysis of the impact of the flow rate on the migration profile for each plasticizer: (table 4a) study 287 
of the interaction time/flow rates and (table 4b) comparisons between flow-rates at any time from the extension lines. 288 
Results were expressed as p-values. 289 
Table 4a 290 
 DEHT TOTM(EL 1) TOTM (EL 2) DINCH (EL 5) DINCH (EL 6) DINP 
Time/flow rate at time 2h 0.17 0.001 0.04 0.89 0.54 0.49 
Time/flow rate at time 4h 0.07 0.20 <0.001 0.63 0.33 0.50 
Time/flow rate at time 8h 0.02 0.28 <0.001 0.91 0.29 0.31 
Time/flow rate at time 24h 0.05 0.44 <0.001 0.85 0.29 0.01 
 291 
Table 4b 292 
 TOTM (EL 1) TOTM (EL 2) DEHT DINP DINCH (EL 5) DINCH (EL 6) 
5mL/h vs 1mL/h 0.125 0.008 <0.001 0.006 <0.001 <0.001 
10mL/h vs 1mL/h 0.015 0.001 <0.001 0.005 <0.001 <0.001 
10mL/h vs 5mL/h <0.001 0.040 0.010 0.003 0.392 0.007 
 293 
 294 
 295 
 296 
Table 5: Statistical analysis of the impact of the flow rate on the migration profile for each plasticizer: (table 5a) study of 297 
the interaction time/flow rates and (table 5b) comparisons between flow-rates at any time from the infusion sets . 298 
Results were expressed as p-values. 299 
Table 5a 300 
 DEHT TOTM DINCH DINP 
Time/flow rate at time 2h 0.78 0.47 0.11 0.45 
Time/flow rate at time 4h 0.71 0.35 0.43 0.35 
Time/flow rate at time 8h 0.70 0.47 0.42 0.30 
Time/flow rate at time 24h 0.82 0.87 0.41 0.38 
 301 
Table 5b 302 
 DEHT TOTM DINCH DINP 
20mL/h vs 8mL/h 0.96 <0.001 <0.001 0.44 
50mL/h vs 8mL/h 0.13 <0.001 <0.001 <0.001 
100mL/h vs 8mL/h 0.05 <0.001 <0.001 <0.001 
50mL/h vs 20mL/h 0.27 <0.001 0.02 <0.001 
100mL/h vs 20mL/h 0.11 <0.001 <0.001 <0.001 
100mL/h vs 50mL/h 0.66 0.02 <0.001 0.95 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
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Discussion 311 
 312 
This study has assessed, for the first time, the impact of the flow rate on the migration of 313 
DEHP alternative plasticizers from medical devices, using two different approaches that are 314 
complementary to characterize this influence.  315 
With the clinical approach, the flow rate does influence the migration of all tested 316 
plasticizers, by increasing the released plasticizer levels in concordance with an increased infusion 317 
rate, leading to higher amounts of plasticizers delivered to the patient after a 24h-period infusion 318 
procedure. Each plasticizer has a specific migrability, as demonstrated in our previous work (7): in 319 
the same conditions, TOTM was found to have the lowest migration rate, followed by DEHT and 320 
then DINCH. We also studied DINP’s migration in this study, which is close to that of DINCH: at 24h, 321 
respectively 1.10% and 1.67% of initial amounts of DINP had been extracted from the extension line 322 
and the infusion set at the highest flow rates of 10mL/h and 100mL/h compared to the 1.50% 323 
(bigger diameter) and 0.82% of DINCH found in the simulant. For TOTM and DEHT, the extracted 324 
levels were much lower: 0.02% (coextruded line) and 0.14% for TOTM and 0.70% and 0.40% for 325 
DEHT at 24h. 326 
Comparisons with other studies assessing the migration of plasticizers under dynamic conditions 327 
could be performed. Most of them have been carried out with DEHP. In the work of Bagel et al, 3 328 
different flow rates were investigated (4): 30, 60 and 90 mL/h. For a same infused volume by 329 
extension lines, the authors showed that about 1000 μg of DEHP is released in 8.33h at 30 mL/h, 330 
600 μg in 4.17h at 60 mL/h and 500 μg in 2.8h at 90 mL/h. In our study, higher levels of DINP 331 
(respectively 17610 μg, 6872 μg and 9961 μg), DINCH (respectively 10060.9 μg, 11285.9 μg and 332 
8393.3 μg), and DEHT (respectively 3687.9 μg, 2672.4 μg and 1745.3 μg) were found in the simulant 333 
after 8h at 20 mL/h, 4h at 50 mL/h and 2h at 100 mL/h. The quantities of TOTM released were much 334 
lower at the same times and speeds: 378.8 μg, 609.1 μg and 489.1 μg.  The same comparisons could 335 
be performed with the work of Rose et al, showing a 500 μg release of DEHP in a propofol solution 336 
and 300 μg in an intralipid solution at 12 mL/h at 24°C during 6h (8). Our results concerning 337 
plasticizer migration levels at 10 mL/h after 8h of infusion are the following: 2071.1 μg of DINP, 338 
1425.8 μg and 11935 μg (large and small diameter) of DINCH, 632.5 μg of DEHT, 40 μg and 561.6 μg 339 
(coextruded and non-coextruded tubing) of TOTM. The amounts of TOTM are even higher after 4h 340 
of dialysis session at 500 mL/h (Kambia et al 2001). All this data is consistent with our study to show 341 
that the flow rate influences the leaching of all the plasticizers to various degrees depending of the 342 
nature of the plasticizer and the simulant. The highest quantities of additives released in the media 343 
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are observed with highest volumes of simulant infused, whereas the migration is more important 344 
with lowest flow rates for a same infused volume. However, data comparison is difficult, because 345 
the experimental conditions are not standardized between the studies in terms of nature and 346 
volume of simulant, flow rates, contact time, temperature, etc… Moreover, in the field of infusion, 347 
two main types of medical devices are used: infusion sets and extension lines that could have a 348 
different influence on the release of plasticizers from the PVC matrix. Our work allows this 349 
comparison, by assessing in standardized conditions different types of infusion devices made of 350 
plasticized PVC, simulating the general clinical practice in adult and pediatric care units. The data 351 
collected demonstrates that the flow rate plays a role in the migration of plasticizers. The migration 352 
kinetic is higher when drugs are infused at lower flow rates but for a given time period, the greater 353 
the flow rate, the higher the level of plasticizer released in the simulant at 24h. This could be easily 354 
explained by the volume infused of the simulant. These differences may have important clinical 355 
implications: patients receiving such IV therapies may be exposed to variable doses of plasticizers 356 
that ideally should remain under the tolerable limit before toxicity, i.e the DNEL (Derived No Effect 357 
Level) which represents the human theoretical dose limit. Considering the largest amounts of 358 
plasticizers quantified in the simulant at 24h (i.e. at a flow rate of 100mL/h), an inpatient of 70 kg is 359 
thus susceptible to be exposed to 0.097mg/kg/d of TOTM, 0.264mg/kg/d of DEHT, 0.77mg/kg/d of 360 
DINCH and 0.96mg/kg/d of DINP. For DINP, the obtained value is above the TDI (Tolerable Daily 361 
Intake) of 0.15 mg/kg/d of the Danish EPA report (9) For DINCH, the value remains beneath the TDI 362 
of 0.15 mg/kg/d of the Danish EPA report or the latest NOAEL limit of 300mg/kg/d for an IV route 363 
administration of DINCH given by the work of David et al (10), considering a DNEL of 3mg/kg/d 364 
(security factor of 100). However, the exposure dose could be considered as toxic, when compared 365 
to the 0.4 mg/kg/d of the NICNAS report (11). For TOTM, as expected, exposure doses are the 366 
lowest of all the plasticizers and are far below the TDI of 1.13mg/kg/d (9).  367 
Nevertheless, to perform a risk assessment according to the flow rate, the entire infusion 368 
therapy should be considered, and not just one infusion procedure per patient. The 369 
physicochemical approach could provide information on the specific migration rates of each PVC 370 
medical device. The migration kinetic is higher when the solvents are infused at lower flow rates, 371 
with major differences between extension lines and infusion sets. The ratios of migration kinetics 372 
between the low and the high flow rate for extension lines were of 8 (non coextruded MD) and 2.3 373 
(coextruded MD) for TOTM, 2.7 for DEHT, 2.1 and 2.6 for DINCH and 1.7 for DINP. 374 
When using the physicochemical approach, the quantities of released plasticizers were 375 
compared by MD surface unit and infused volume in order to assess the real impact of the flow 376 
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rates on the different types and models of our studied medical devices. We showed that there was 377 
no significant difference of the migration kinetic profiles depending on the flow rate for a same 378 
medical device. Notably, quantities of DEHT released were the same whatever the time of kinetic, 379 
which suggests an atypical behavior of the plasticizer. 380 
These results highlight that the migration of plasticizers is very variable depending on the type of 381 
medical devices: 382 
- type and use: the infusion sets are especially used for the administration of high volumes of 383 
drug solutions by gravity whereas the extension lines allow a more controlled and precise 384 
administration of only tens of milliliters of emergency drugs including some with a narrow 385 
therapeutic range. Moreover, the different administration positions (i.e vertical position for the 386 
infusion sets and horizontal for the extension sets) may influence the migration by influencing the 387 
surface interactions between the plasticizers and the simulant. The results highlight that the 388 
migration of plasticizers varies greatly with the type of medical device. Indeed, the quantities 389 
released at 24h for a flow rate of 10 mL/h with an extension line made of non-coextruded 390 
PVC/TOTM were of 25 µg/dm²/mL whereas they reached 600 µg/dm²/mL at 24h for a flow rate of 391 
10mL/h with an infusion set made of non-coextruded PVC/TOTM, i.e a ratio of 24. For the other 392 
plasticizers, the same ratios are 18.8; 13.7 and 5 for DINCH, DEHT and DINP respectively.   393 
Moreover, a greater variability occurred during the migration assays with infusion sets versus 394 
extension lines. The main reason for this is that the flow rate was set up manually for the infusion 395 
sets unlike the automatic syringe pump administrations used for the tests using the extension lines. 396 
- diameter: the migration kinetic of DINCH is almost 2 times lower when the inner diameter 397 
is 2.5 times higher (EL5 vs EL6), although a higher volume of simulant (with the larger diameter of 398 
the MD) does finally extract a higher quantity of plasticizer (see result section figure 5). This might 399 
be explained by different plasticizer/solvent interactions with the inner surface of the PVC and thus 400 
by the matrix penetration of the solvent. Indeed, it has been demonstrated that the storage 401 
conditions (i.e the simulant in contact with the PVC surface) could impact the characterization of 402 
the surface physico-chemistry, especially during a contact with ethanol. In the work of Salloum et al 403 
(12), the infusion MD surfaces are modified and even altered by the solvent during storage. The 404 
roughness of the surface, the size and the distribution of cracks on the surface are variable and 405 
depend on the type and composition of the MD and the duration of the contact. They showed that 406 
it leads to different leaching rates of the additives. In our study, the interactions between the 407 
ethanolic simulant and the PVC surface of the two extension lines containing DINCH as main 408 
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plasticizer are different because of the specific changes on the surface occurring during the assays 409 
according the flow rate (different contact time) and the manufacturing process of the MDs. 410 
- composition of the PVC matrix: we clearly demonstrated that the polyethylene layer has a 411 
protect effect on the migration of TOTM, lowering its migration rate by more than 2 times. As it has 412 
already been shown that coextruded extension lines avoid the drug sorption on PVC (4),(13), such 413 
devices should be used first in clinical practice. Moreover, all the medical devices tested in our work 414 
are composed of plasticized PVC with different initial quantities of plasticizers: extension lines 415 
contain 26.7% of DEHT, 31.8% (coextruded) and 30.3% (non coextruded) of TOTM, 30.6% (large 416 
diameter) and 35.7% (small diameter) of DINCH and 48.7% of DINP; whereas the infusion sets 417 
contain 37.5% of DEHT, 41% of TOTM, 44.3% of DINCH and 34.9% of DINP.  418 
These differences should be linked to the higher variability observed with DEHT released from the 419 
infusion set. They probably also rely on the specific technicality of the gravity infusion set made of 420 
PVC/DEHT (provided by BBraun), although generally, more variability occurred during the migration 421 
assays with infusion sets versus extension lines. Moreover, the lower leaching aptitude into oily 422 
media of DEHT (i.e ethanolic simulant) compared to other studied plasticizers (14) could have 423 
influenced the interactions between DEHT and the simulant. To check this assumption regarding the 424 
infusion set supplied by BBraun (Intrafix Safeset), some additional migration assays were performed 425 
(see supplementary file n°1). The results confirm a higher variability rate due to the gravity 426 
technique (no variability appeared with the same tubing during an infusion with a syringe pump) 427 
and furthermore, provided particularly by this infusion set (less variability was observed with 428 
another infusion set). 429 
Overall, these results suggest that the migration rate is less influenced by the flow rate than 430 
by the nature and the composition of the medical device, reflecting complex interactions between 431 
the PVC matrix and the simulant, combined with the volume of the infused drug to patient. This 432 
may explain a different diffusion ratio for each plasticizer inside the PVC matrix, as it has been 433 
demonstrated by Al Salloum et al, by using a coupling Raman confocal microscopy to UV 434 
spectroscopy technique (15). We thus recommend that the flow rate be taken into account in the 435 
risk assessment of the plasticizers’ migration if the tested MD are likely to be used in conditions 436 
significantly different in terms of flow rate (which may lead to significant differences in the technical 437 
characteristics of tested MD). 438 
 439 
 440 
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Conclusion 441 
 442 
This study provides information about the real influence of the flow rate on the migration of 443 
plasticizers from PVC medical devices used in infusion conditions. The two approaches developed in 444 
our study complementarily characterize this influence. From a clinical view, higher speeds led to 445 
higher amounts of plasticizers released to inpatients for a fixed contact time of 24h. On the other 446 
side, from a physicochemical view, there was no significant difference of the migration kinetic in 447 
relation to the flow rate at each contact point of a same medical device. An increased consideration 448 
to the specific features of a medical device should be given, in order to assess patients’ exposure 449 
risk to alternative plasticizers. The different PVC tubing tested in this study are given as examples 450 
and reflect that the risk evaluation should be completed, including all the specific environment 451 
parameters. More information could be obtained by profile analyses of the PVC matrix in order to 452 
understand specific migration mechanisms according to the composition of the PVC matrix, which 453 
could help to develop solutions to prevent these surface interactions. 454 
 455 
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